---
title: "DRUG.US (DRUG.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DRUG.US/news.md"
symbol: "DRUG.US"
name: "DRUG.US"
parent: "https://longbridge.com/en/quote/DRUG.US.md"
datetime: "2026-05-21T18:21:29.857Z"
locales:
  - [en](https://longbridge.com/en/quote/DRUG.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DRUG.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DRUG.US/news.md)
---

# DRUG.US (DRUG.US) — Related News

### [Psychedelic Stocks Just Went Mainstream](https://longbridge.com/en/news/283667440.md)
*2026-04-22T12:37:22.000Z*
> Donald Trump signed an executive order to accelerate research and access to psychedelic therapies, backed by $50 million

### [Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use](https://longbridge.com/en/news/283388595.md)
*2026-04-20T18:02:21.000Z*
> Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use

### [Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research](https://longbridge.com/en/news/281016411.md)
*2026-03-30T12:08:43.000Z*
> BTIG Research has reiterated a "buy" rating for Bright Minds Biosciences (NASDAQ:DRUG) with a target price of $147.00, i

### [Havas Health and BrightInsight Forge Exclusive Alliance to Tackle Pharma's $500B+ Patient Problem](https://longbridge.com/en/news/277059428.md)
*2026-02-26T14:15:00.000Z*
> Havas Health has formed an exclusive partnership with BrightInsight to address patient adherence issues in the pharmaceu

### [Canadian Securities Exchange Reports January 2026 Performance Figures](https://longbridge.com/en/news/276140465.md)
*2026-02-17T15:09:11.000Z*
> The Canadian Securities Exchange (CSE) reported strong performance figures for January 2026, with trading volume reachin

### [De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise](https://longbridge.com/en/news/275923532.md)
*2026-02-13T15:45:31.000Z*
> TD Cowen analyst Joseph Thome has maintained a Buy rating on DRUG stock, citing strong clinical performance of BMB-101 i

### [Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5%](https://longbridge.com/en/news/274396752.md)
*2026-01-31T20:55:09.000Z*
> Bright Minds Biosciences Inc. (NASDAQ:DRUG) experienced a significant increase in short interest, rising by 67.5% in Jan

### [Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/272226940.md)
*2026-01-12T06:49:44.000Z*
> Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received a consensus rating of "Moderate Buy" from eight research firms.

### [Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen](https://longbridge.com/en/news/272143948.md)
*2026-01-10T06:18:33.000Z*
> Wall Street Zen downgraded Bright Minds Biosciences (NASDAQ:DRUG) from a "hold" to a "sell" rating. Despite this, severa

### [Bright Minds Biosciences Announces Closing of US$175 Million Public Offering  | DRUG Stock News](https://longbridge.com/en/news/272106227.md)
*2026-01-09T08:56:00.000Z*
> Bright Minds Biosciences Inc. has successfully closed a public offering of 1,945,000 common shares at US$90.00 each, rai